RenovoRx Establishes RenovoCath® Medical Advisory Board

Core Insights - RenovoRx has established a Medical Advisory Board (MAB) to enhance its TAMP™ therapy platform, focusing on clinical indications with high unmet medical needs [1][2][5] Group 1: Medical Advisory Board Formation - The MAB consists of leading US interventional radiology experts who will provide strategic clinical insights to advance the TAMP therapy platform [2][3] - The MAB will complement the existing Scientific Advisory Board, which focuses on scientific research and clinical program strategy [2] Group 2: Clinical and Market Strategy - The MAB will support ongoing clinical and market strategies and provide insights into potential investigator-initiated trials, which are designed to broaden the application of the TAMP platform [3] - Current trials supported by RenovoRx include studies on borderline resectable and metastatic pancreatic cancer, with potential for expanding targeted indications [3] Group 3: Feedback and Market Introduction - The MAB will also provide feedback to the sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications [4] Group 4: RenovoCath Overview - RenovoCath is an FDA-cleared drug-delivery device intended for targeted therapeutic delivery across the arterial wall near tumor sites, aiming to minimize toxicities compared to systemic intravenous therapy [12][13] - The device is also indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [12] Group 5: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices, generating approximately $900,000 in revenue for the first nine months of 2025 [14] - The company is actively exploring further revenue-generating activities to meet anticipated demand [14] Group 6: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [15][16] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [17]